Stockwinners Market Radar for April 04, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:15 EDT Cathie Wood's ARK Investment bought 138K shares of 10x Genomics today

19:50 EDT Selecta Biosciences Inc trading halted, news pending

19:50 EDT Gladstone Capital trading halted, news pending

18:52 EDT GAP Airports reports preliminary March passenger traffic down 0.6% - Grupo Aeroportuario del Pacifico announces preliminary terminal passenger traffic figures for March 2024, compared with March 2023. For March 2024, the total number of terminal passengers at GAP's 12 Mexican airports decreased by 1.2%, compared to March 2023. Puerto Vallarta and Los Cabos presented an increase in passenger traffic of 5.7% and 1.2%, while Tijuana and Guadalajara airports presented a decrease in passenger traffic of 5.0% and 2.4%, respectively, compared to March 2023. On the other hand, Montego Bay presented an increase in passenger traffic of 6.4% compared to March 2023.

18:22 EDT Grifols says all liabilitites disclosed in audited financial statements - Grifols board secretary Nuria Martin Barnes said, "Based on the misinterpretation generated after the publication of Grifols' response to the CNMV requirements, we would like to clarify that all of Grifols' liabilities have already been included and disclosed in the audited financial statements published on March 8th, 2024, and confirmed by the regulator. The EUR1.1B is not a financial debt as it is related to the future rentals of the properties of more than 390 plasma donation centers worldwide and, therefore, does not represent any new debt."

17:30 EDT Semantix Inc trading resumes

17:15 EDT Aecom, Fluor among consortium awarded $2.0B contract by U.S. Navy - AECOM-ASO JV, Amentum Services Inc., Fluor Intercontinental Inc, KBR Services and Vectrus Systems Corp. are awarded a combined $2,000,000,000 indefinite-delivery/indefinite-quantity contract with the capability to issue cost-plus-award-fee and firm-fixed-price task orders for the Global Contingency Services Multiple Award Contract III. This contract provides for the ability to quickly provide short-term facility support services in support of natural disasters, humanitarian efforts, the full range of military actions, incumbent contractor's nonperformance or potential breaks in service. Work will be performed at various locations (including remote locations) throughout the world. The term of the contract is not to exceed 102 months and is expected to be completed by September 2032. The maximum dollar value, including the base period and seven option years with one six-month extension period, for all six contracts combined, is $2,000,000,000. Each awardee will be awarded $25,000 at contract award.

17:02 EDT Semantix announces voluntary delisting from Nasdaq Global Market - Semantix announced that it has notified the Nasdaq Stock Market LLC of its decision to voluntarily delist its ordinary shares, par value $0.001 per share and its warrants exercisable for one Ordinary Share at an exercise price of $11.50 from the Nasdaq Global Market. As previously noted in the company's Report on Form 6-K filed with the Securities and Exchange Commission on January 5, 2024, the Company received written notice from Nasdaq that the Company was not in compliance with the minimum bid price required for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1) based upon the closing bid price of the Ordinary Shares for the 34 consecutive business days prior to the date of the notice. Semantix intends to file a Form 25 with the SEC to remove its Ordinary Shares and Warrants from listing on the Nasdaq Global Market on or about April 15, 2024 and deregister such securities under Section 12(b) of the Securities Exchange Act of 1934, as amended, and as a result, Semantix expects that the last trading day of its Ordinary Shares and Warrants on the Nasdaq Global Market will be on or about April 12, 2024. Furthermore, prior to April 30, 2024, the Company intends to file a Form 15 with the SEC to suspend the Company's reporting obligations under Sections 12(g) and 15(d) of the Exchange Act.

16:55 EDT Semantix Inc trading halted, news pending

16:32 EDT Nucor introduces weekly hot-rolled coil spot pricing - Nucor is introducing a weekly Nucor Consumer Spot Price - CSP - to provide its customers with communications regarding the company's hot-rolled coil spot pricing. Nucor will issue the first CSP on Monday, April 8. The CSP will be released every Monday, communicating Nucor's hot-rolled spot price for the week to Nucor customers. It will remain in effect until the next weekly publication. Nucor CSP pricing will be derived from both quantitative and qualitative data. Lead times for all spot orders will be offered between three and five weeks to assist customers with their planning.

16:25 EDT GameStop announces COO Nir Patel to depart - In a regulatory filing, GameStop disclosed that on April 4, GameStop and Nir Patel, COO, entered into a Separation Agreement and Mutual Release of Claims. The Separation Agreement provides for Patel's departure from the company, effective April 4, as the company's COO. The responsibilities associated with the position are being absorbed by other members of the company's management team.

16:22 EDT RxSight launches its newest light adjustable lens, the LAL+ - RxSight announced the commercial launch of its newest Light Adjustable Lens, the LAL+. The company now offers two lenses in the Light Adjustable Lens platform: the LAL and the Light Adjustable Lens+, LAL+ . The LAL+ has a modified aspheric anterior surface that creates a small continuous increase in central lens power, which is designed to slightly extend the depth of focus. In addition, RxSight's Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens , RxSight Light Delivery Device and accessories, will be the subject of various doctor presentations at the annual meeting of the American Society of Cataract and Refractive Surgery,ASCRS, in Boston on April 5-8.

16:18 EDT Valaris discloses notice of suspension from Aramco for VALARIS 143 - Valaris Limited announced that ARO Drilling, its joint venture in Saudi Arabia, received a notice of suspension from Aramco for one of its 19 contracted rigs, jackup VALARIS 143. The rig's contract was previously scheduled to end in December 2024. The suspension notice is for a period of up to twelve months and ARO is in discussions with Aramco to determine the effective date of the suspension. During the suspension period, ARO will have the right to terminate the drilling contract with Aramco. Valaris leases VALARIS 143 to ARO under a bareboat charter agreement.

16:15 EDT Sensei Biotherapeutics: Peer-reviewed research paper on SNS-101 published - Sensei Biotherapeutics announced the publication of a peer-reviewed research paper in Nature Communications. The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine. The paper describes Sensei Biotherapeutics' approach to the discovery and development of SNS-101, which was designed to potently and selectively target the active protonated form of VISTA, a protein that plays a significant role in suppressing T-cell activation. VISTA was previously considered undruggable due to its extensive expression on myeloid cells, leading to safety issues such as cytokine release syndrome CRS , in addition to a pharmacokinetic sink, which poses a significant challenge in reaching therapeutically relevant concentrations. The paper details the mechanism and characteristics of SNS-101, a novel pH-sensitive monoclonal antibody. SNS-101 was shown to bind to a novel epitope of VISTA that is remodeled under low pH conditions, switching VISTA into an active state that engenders extensive T-cell suppression. SNS-101 is designed to block VISTA by inhibiting its interaction with PSGL-1 on T-cells resulting in T-cell activation. Subsequently, in various preclinical models, SNS-101 was shown to mitigate CRS risk and maintain a favorable pharmacokinetic and safety profile, all of which had thwarted the clinical development of first generation, non-pH sensitive anti-VISTA antibodies.

16:12 EDT Invivyd gets EUA from FDA for Pemgarda in COVID-19 in adults and adolescents - On March 22, PEMGARDA pemivibart injection, for intravenous use, received emergency use authorization EUA from the U.S. Food and Drug Administration FDA for the pre-exposure prophylaxis of COVID-19 in adults and adolescents who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2. "I am very pleased to announce that, in less than two weeks from receiving EUA, PEMGARDA is now commercially available for order across the U.S.," said Dave Hering, Chief Executive Officer. "This is a remarkable achievement for our organization and for the immunocompromised individuals we serve. With product now available, today we are providing initial PEMGARDA net product revenue guidance in the range of $150Mto $200M for the full year 2024. Based on this anticipated net product revenue and our continued optimization of operating expenses, we expect to end 2024 with at least $55M in cash and cash equivalents."

16:08 EDT Vimeo appoints Philip Moyer as CEO - Vimeo announced the appointment of Philip Moyer as CEO and member of the board effective April 8. Adam Gross, the company's interim CEO and member of the board, will remain on the Board after the transition. Moyer previously served as Global VP of Applied AI Engineering and Business Development and VP of Strategic Industries, Google Cloud, a division of Alphabet (GOOG), a role he held since July 2019.

16:07 EDT Sterling Infrastructure CEO Cutillo sells 19,674 common shares - In a regulatory filing, Sterling Infrastructure CEO Joseph Cutillo disclosed the sale of 19,674 common shares of the company on April 2 at a price of $105.569 per share.

16:06 EDT FDA clears Caribou's IND application for CB-010 to treat lupus and ERL - Caribou Biosciences announced that it received clearance of its Investigational New Drug, IND, application from the U.S. Food and Drug Administration FDA for CB-010, an allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout KO, for the treatment of lupus nephritis LN and extrarenal lupus ERL. The Phase 1, multicenter, open label GALLOP clinical trial of CB-010 in patients with LN and ERL is expected to initiate by year-end 2024. "CB-010 has demonstrated encouraging initial safety and efficacy in patients with relapsed or refractory B cell non-Hodgkin lymphoma, and we are excited to expand CB-010's clinical development to include autoimmune diseases," said Rachel Haurwitz, PhD, Caribou's president and chief executive officer. "By targeting CD19-positive B cells involved in the production of autoantibodies and the perpetuation of the autoimmune response, our off-the-shelf CAR-T cell therapy CB-010 has the potential to greatly improve the standard of care for patients with lupus, a prevalent and severe autoimmune disease." CB-010 is the lead clinical-stage product candidate from Caribou's allogeneic CAR-T cell therapy platform. As previously reported, CB-010 has demonstrated encouraging initial safety and efficacy from the dose escalation portion of the ongoing ANTLER Phase 1 trial in patients with relapsed or refractory B cell non-Hodgkin lymphoma r/r B-NHL . Caribou continues to enroll patients with large B cell lymphoma LBC in the second-line setting, and initial dose expansion data from ANTLER will be presented at a medical congress in Q2. "Despite treatment advancements, fatigue, organ damage, and low health-related quality of life often remain life-long characteristics of lupus," said Richard Lafayette, MD, professor of medicine, Stanford Medicine Health Care. "An allogeneic anti-CD19 CAR-T cell therapy from healthy donor T cells has the potential to revolutionize lupus treatment, offering a readily available treatment for patients who need new therapeutic options." Caribou continues to expect the $372.4M cash, cash equivalents, and marketable securities, as of December 31 to fund the current operating plan into Q1 2026.

16:00 EDT Value Line trading resumes

13:16 EDT Keyarch Acquisition Corp trading resumes

13:01 EDT Keyarch Acquisition Corp trading halted, volatility trading pause

12:43 EDT Vitru Ltd trading halted, volatility trading pause

12:22 EDT Binah Capital Group Inc trading resumes

12:01 EDT McDonald's acquires 225 restaurants in Israel from Alonyal - Omri Padan, CEO and owner of Alonyal Limited, announced that an agreement to sell Alonyal to McDonald's Corporation has been signed. Alonyal, which owns and operates McDonald's restaurants in Israel, started McDonald's in Israel more than 30 years ago and has grown the business to 225 restaurants and more than 5,000 employees. Upon completion of the transaction, McDonald's will own Alonyal Limited's restaurants and operations, and employees will be retained on equivalent terms.

12:00 EDT Paragon 28 falls -11.8% - Paragon 28 is down -11.8%, or -$1.42 to $10.64.

12:00 EDT Levi Strauss rises 15.3% - Levi Strauss is up 15.3%, or $2.85 to $21.51.

12:00 EDT Allurion Technologies rises 92.5% - Allurion Technologies is up 92.5%, or $1.60 to $3.33.

11:13 EDT Dogness Internationa trading halted, volatility trading pause

10:46 EDT Cleveland-Cliffs 'applauds' DOE's final transformer efficiency standard rule - Cleveland-Cliffs "applauded" the Department of Energy's final transformer efficiency standard rule that will provide for the continued utilization of Grain-Oriented Electrical Stee in virtually all of Cliffs' current distribution transformer end markets. The company said: "With this revised rule, the DOE acknowledged the fundamental importance of GOES and the essential role played by Cleveland-Cliffs steel plants in Butler, PA and Zanesville, OH in effectively sustaining the functionality of the U.S. electric grid. Cleveland-Cliffs and the United Auto Workers worked collaboratively to educate the DOE on the shortcomings of the originally proposed distribution transformer rule and the danger of relying on Amorphous Metal, which is produced in very limited volumes and exclusively from imported materials."

10:23 EDT Nuburu announces $3M capital infusion by strategic investors, customer orders - NUBURU announced a $3M investment in the company's common stock by strategic investors focused on strengthening and growing the company, as well as initial purchase orders from new customers in new markets. Brian Knaley, the Company's CEO, noted that, "The customer qualification process for our products can be lengthy and complex, but we are finally seeing the fruits of our efforts. We have orders to fill in critical new markets and with new customers and we believe this investment will accelerate our fulfillment process and path towards consistent revenue generation. We are excited about growth opportunities that we can pursue with help from investors who see the company's potential." Among the new orders, the company has been awarded an initial purchase order to supply BL-300s to a manufacturer of battery systems in the sustainable energy market, with manufacturing capabilities primarily in Asia. In connection with the strategic investment, the company intends to call a special meeting of stockholders to, among other things, approve the issuance of additional common stock for the purpose of acquiring controlling and non-controlling interests in one or more entities.

10:04 EDT Coinbase obtains registration as Restricted Dealer in Canada - Coinbase has been registered as a Restricted Dealer by the Canadian Securities Administrators, making Coinbase the first international and largest cryptocurrency exchange to be registered in Canada. This milestone, following its formal launch in August 2023, reinforces Coinbase's commitment to Canada as a Go Deep market. The registration is the culmination of months of work, starting in March 2023 when Coinbase signed an Enhanced Pre-Registration Undertaking that signified its dedication to regulatory compliance and operational excellence. Throughout this process, Coinbase closely collaborated with Canadian regulators to establish a policy framework that serves as a global benchmark. Furthermore, Coinbase collaborated with Canadian banks, investment advisors, and pension funds to demonstrate its dedication to facilitating its successful navigation of the evolving digital asset realm.

10:01 EDT Izea reports Q1 Managed Services bookings up 53% y/y to $9.3M - IZEA Worldwide announced its Managed Services team secured contract bookings totaling $9.3M in the first quarter of 2024, a 53% increase from $6.1M in the first quarter of 2023. "In the first quarter of 2024, Managed Services bookings experienced a resurgence in year-over-year growth, propelled by an impressive sales pipeline from the fourth quarter of 2023 and an all-time record-setting pipeline in the opening quarter of this year," said Ted Murphy, Founder, Chairman and CEO of IZEA. "More than 90% of the bookings this quarter have been organic, meaning they were not derived from acquisitions but rather from our own internal growth efforts."

10:00 EDT GCT Semiconductor falls -8.2% - GCT Semiconductor is down -8.2%, or -57c to $6.29.

10:00 EDT HubSpot rises 9.7% - HubSpot is up 9.7%, or $61.03 to $687.73.

10:00 EDT Levi Strauss rises 19.2% - Levi Strauss is up 19.2%, or $3.58 to $22.24.

09:56 EDT Blue Orca Capital short Dayforce on 'accounting maneuvers, unjustified premium' - In a recently published report, Blue Orca Capital says it is short Dayforce, "an S&P 500 human capital management business which we believe engages in highly aggressive revenue recognition and accounting maneuvers to inappropriately pull forward revenues and inflate profits." Blue Orca says it also believes "Dayforce manipulates key profitability metrics which not only misleads investors but unjustly enriches management, whose compensation is tied to such bogus profitability metrics or directly benefit from the Company's aggressive accounting." "Dayforce is plagued by worst-in-class GAAP gross margins, yet its stock trades at an unjustified 25%+ premium above other human capital management companies... Once we adjust Dayforce's financials to remove the impact of inappropriately pulled forward revenues, accounting gymnastics, and non-industry standard cost exclusions, we estimate that Dayforce trades at an eye-popping 38.8x FY23 adjusted EBITDA and 56.9x FY23 adjusted EBIT. An apples-to-apples comparison to other HCM companies implies a ~50% downside for the stock," the report adds. Shares of Dayforce have dropped about 2.5% to $63 in morning trading. Reference Link

09:47 EDT Conagra Brands rises 6.4% - Conagra Brands is up 6.4%, or $1.85 to $30.91.

09:47 EDT Levi Strauss rises 16.5% - Levi Strauss is up 16.5%, or $3.08 to $21.74.

09:47 EDT BrightView falls -9.9% - BrightView is down -9.9%, or -$1.21 to $10.97.

09:46 EDT SWVL Holdings Corp trading resumes

09:43 EDT HubSpot trading resumes

09:38 EDT HubSpot trading halted, volatility trading pause

09:35 EDT FibroBiologics presents data from dermal fibroblast spheroid-based treatment - FibroBiologics announced data from its latest study in a diabetes mouse model on the potential therapeutic efficacy of dermal fibroblast spheroids in treating chronic wounds. These findings will be presented via an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, MA, April 16-17. Diabetic foot ulcers are prevalent in individuals with diabetes, with approximately 33 million people impacted globally. DFUs pose significant challenges for patients and the healthcare system due to impaired healing mechanisms associated with hyperglycemia, cellular senescence, and other comorbidities associated with diabetes. FibroBiologics' research aims to address this issue by investigating the potential of using human dermal fibroblast spheroids in promoting and accelerating the wound healing process in diabetic patients. The study, led by a team of researchers including FibroBiologics' Chief Scientific Officer, Hamid Khoja, Ph.D., utilized a diabetic mouse model to evaluate the therapeutic effects of HDF spheroids on mice with wounds resembling DFUs. Key findings from the study include: Acceleration of wound healing with a 60% decrease in relative wound area within 4 days post-treatment with a single administration of HDF spheroids compared to standard of care treatment control. Upregulation of pro-inflammatory cytokines such as interferon-gamma, and tumor necrosis factor-alpha, along with anti-inflammatory cytokines IL-6 and IL-10, indicating modulation of the wound microenvironment conducive to healing. Increased levels of vascular endothelial growth factors and endothelial growth factor receptors, suggesting enhanced revascularization and re-epithelialization in HDF-treated wounds. Immunohistochemical analysis revealing the presence of markers indicative of fibroblast and endothelial proliferation, active cell proliferation, angiogenesis, and macrophage proliferation in HDF-treated wounds.

09:32 EDT Co-Diagnostics appoints Richard Abbott as president - Co-Diagnostics announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the company naming David Nielsen to be its Chief Operations Officer, Christopher Thurston as its Chief Technology Officer, and Seth Egan as Chief Commercialization Officer. Prior to his new role at the Company, Richard Abbott served as the President of Advanced Conceptions, Inc., a wholly-owned subsidiary of Co-Diagnostics since December 2021.

09:30 EDT SWVL Holdings Corp trading halted, volatility trading pause

09:26 EDT Allarity announces 1-for-20 reverse stock split - Allarity Therapeutics announced the implementation of a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20. The stock will begin trading on a split-adjusted basis when the market opens on April 9. "This strategic move aims to regain compliance with the Nasdaq's minimum bid price requirement, alongside achieving other operational benefits," the company said in a statement.

09:23 EDT Blackline Safety announces $1.4M deal to protect 800 water utility workers - Blackline Safety announced a new deal valued at $1.4M with a water utility provider based in Australia. After commissioning a third-party analysis that named Blackline Safety devices the best lone worker solution on the global market, the corporation selected Blackline and their Australian Channel Partner to provide Blackline's lone worker safety app, Loner Mobile, and G7c cloud-connected devices. This is the latest in a series of deals Blackline Safety has announced with water utility providers in recent years. Blackline Safety devices currently protect half of the water and wastewater companies in the United Kingdom.

09:17 EDT Riot Platforms reports $685M in cash and 8,490 unencumbered Bitcoin at March-end - Riot ended the month with approximately $685M in cash on hand and 8,490 unencumbered Bitcoin on the balance sheet, representing total liquidity of approximately $1.3Bas of the end of March 2024 based on the month-end market price of Bitcoin. As of the end of March 2024, Riot had approximately 268M shares outstanding.

09:16 EDT Wolters Kluwer launches AI-powered OneSumX Reg Manager - Wolters Kluwer Compliance Solutions has launched OneSumX Reg Manager to help U.S. community banks and credit unions enhance their regulatory change management efforts. This artificial intelligence-powered solution represents the latest addition to the Compliance Solutions OneSumX portfolio suite, a trusted product line designed to help financial institutions across the U.S. more effectively navigate regulatory change.

09:15 EDT Bit Origin explores use of 'Artificial Intelligence' in crypto mining - Bit Origin announces that it actively explores the use of Artificial Intelligence AI in crypto mining. As the world of cryptocurrency continues to evolve and innovate, the crypto mining industry is undergoing a significant transformation, driven by the integration of AI. This groundbreaking convergence promises to revolutionize mining operations, enhancing efficiency, sustainability, and profitability.The marriage of AI and crypto mining offers unprecedented opportunities for optimization across the entire mining process. By leveraging AI-powered algorithms and machine learning capabilities, mining operations can streamline processes, maximize resource utilization, and minimize energy consumption....By harnessing the power of AI, crypto mining companies can unlock new levels of efficiency, sustainability, and profitability in an increasingly competitive landscape. As the crypto mining industry undergoes this transformative shift, Bit Origin is determined to explore the potential ofv AI-driven solutions to unlock value and drive sustainable growth.

09:13 EDT Kaua'i Federal Credit Union selects Upstart for personal lending - Kaua'i Federal Credit Union has announced a new partnership with Upstart, the leading artificial intelligence lending marketplace, to provide personal loans to new and existing members. "We welcome Kaua'i Federal Credit Union to the Upstart family of lending partners," said Michael Lock, Senior Vice President of Lending Partnerships for Upstart. "As a lending partner on the Upstart Referral Network, Kaua'i Federal Credit Union is there to provide more creditworthy people in its community with access to affordable credit."

09:12 EDT Microsoft, Cloud Software Group sign 8-year strategic partnership agreement - Cloud Software Group and Microsoft Corp. announced they are deepening their collaboration through an eight-year strategic partnership agreement. The collaboration will strengthen the go-to-market collaboration for the Citrix virtual application and desktop platform and support the development of new cloud and AI solutions with an integrated product roadmap. Additionally, Cloud Software Group will make a $1.65 billion commitment to the Microsoft cloud and its generative AI capabilities.

09:11 EDT Riot sees Corsicana facility to have 1 GW of developed mining capacity - Riot is currently developing Phase 1 of the Company's second large-scale facility, the Corsicana Facility, which is expected to have 400 megawatts of developed mining capacity upon completion of this initial phase. Once fully developed, the Corsicana Facility is expected to have 1 gigawatt in total developed mining capacity. In March, the immersion systems in the first 100 MW building, Building A1, were installed, and miner installation commenced. The 400 MW substation is expected to be energized in the first half of April 2024, and Building A1 will commence operations shortly thereafter. Onsite development teams have completed the foundation for the second 100 MW building, Building A2, and construction of the building has begun. Immersion systems will begin to be installed in Building A2 during the month of April, with operations expected to commence in Q2 .

09:11 EDT Acadia Healthcare appoints Stephanie Eken as Chief Medical Officer - Acadia Healthcare Company announced the appointment of Dr. Stephanie Eken as the Company's new chief medical officer. Dr. Eken brings more than two decades of experience across the behavioral health domain into this new role. She joins Acadia after spending 15 years at Rogers Behavioral Health.

09:09 EDT Quad/Graphics announces new predictive model of consumer attitudes - Quad/Graphics has developed a specialized attitudinal model that helps health insurers drive deeper connections with consumers while reducing the costs to acquire and serve members. The model is based on nationally representative, primary research about what consumers value most from their health insurance. "Marketers know segmentation is critical, but relying solely on traditional inputs like demographics, response or conversion just isn't enough in today's oversaturated marketplace," said Jennifer Hickman, Head of Strategy for Health at Quad.

09:08 EDT Safe and Green Development announces XENE Home AI beta launch - Safe and Green Development announced the Beta launch of the Xene AI Platform for the Real Estate industry. During the beta launch phase those who signed up on the waiting list to test the platform's innovative features will be granted early access to the platform to provide valuable feedback before the official launch to the entire real estate industry licensee base and public. This phase will allow our stakeholders to enjoy access to the platform and discover some of the initial AI features of the platform. The fully developed platform is expected to launch in the coming weeks. XENE is designed to assist customers, including buyers and sellers, real estate agents, lawyers, accountants and title companies in many facets of various real estate transactions by enhancing the transaction process with cost-efficiencies and reduced transaction fees in a range of 1.99% to 3.99% per transaction. Licensed real estate professionals who join the Xene Home platform will gain access to premium exclusive listings, dedicated buyers, traditional leads, and exclusive certification tools, all of which are intended to enhance the industry professional's portfolio and both enhance and expand their business reach and performance metrics.

09:07 EDT CTO Realty Growth prices 1.5M shares at $20.00 in public offering - CTO Realty Growth announced the pricing of a public offering of 1,500,000 additional shares of the Company's 6.375% Series A Cumulative Redeemable Preferred Stock, liquidation preference $25.00 per share, at a public offering price of $20.00 per share. CTO will receive gross proceeds of $30,000,000 from the sale of the Series A Preferred Stock before deducting the underwriting discount and other estimated offering expenses. The Company also granted the underwriters a 30-day option to purchase up to an additional 225,000 shares of the Series A Preferred Stock to cover over-allotments, if any. The additional shares of Series A Preferred Stock constitute an additional issuance of shares of Series A Preferred Stock, with 2,978,808 shares of Series A Preferred Stock currently issued and outstanding. The Series A Preferred Stock will be treated as a single series with and have the same terms as the Outstanding Series A Preferred Stock. The Outstanding Series A Preferred Stock is, and the Series A Preferred Stock sold in the offering will be, listed on the New York Stock Exchange under the ticker symbol "CTO PrA." The offering is expected to close on April 11, 2024, subject to customary closing conditions. CTO intends to use the net proceeds from the offering for general corporate and working capital purposes, which may include property acquisitions, commercial loan and investment opportunities and repayment of debt, including amounts outstanding under its credit agreement. Raymond James & Associates, Inc. is acting as book-running manager for the offering. BMO Capital Markets Corp., KeyBanc Capital Markets Inc., Baird, PNC Capital Markets LLC, B. Riley Securities, Inc., Janney Montgomery Scott LLC, JonesTrading Institutional Services LLC, Regions Securities LLC and Synovus Securities Inc. are acting as co-managers for the offering.

09:00 EDT AXT Inc. sinks 18% to $4.05 after J Capital short report

08:58 EDT LQR House enters marketing partnership with Kamoti - LQR House announced its latest marketing partnership with Kamoti, aimed at enhancing its brand visibility and boosting its sales on CWSpirits.com through targeted marketing services. Under this strategic alliance, Kamoti has engaged LQR House to craft a tailored campaign aimed at amplifying awareness of its green and white tea shot beverages. Leveraging LQR House's variety of marketing tools, including banner ads, email marketing, and influencer outreach, the campaign seeks to drive targeted traffic to CWSpirits.com and bolster sales for Kamoti's innovative green tea shots.

08:57 EDT LightPath announces commercial availability of BDNL-4 glass - LightPath Technologies announced the commercial launch of its first new BlackDiamond-NRL infrared glass, BDNL-4, a key material in the chalcogenide glass series licensed from the US Naval Research Laboratories as a substitute for Germanium. BDNL-4 is a new material that exhibits a negative thermo-optic coefficient, an important attribute for making systems athermalized, enabling the design of devices that are unaffected by temperature changes. BDNL-4 is also a true multi-spectral material that can be used across SWIR, MWIR and LWIR imaging bands. As with all its Chalcogenide materials, LightPath offers antireflective and protective DLC coatings for the new BDNL-4 materials. Following years of development at NRL, BDNL-4 is licensed exclusively to LightPath.

08:54 EDT Twin Vee PowerCats launches next generation of GFX model line - Twin Vee PowerCats announced the launch of the all-new second generation of its GFX model line that features a multitude of design, styling, and technological innovations that is expected elevate the Twin Vee brand above its competitors as well as the impressive legacy of the first-generation of GFX boats. The second generation of the GFX model line, or GFX-2 for short, will feature five lengths ranging in size from 24 feet to 40 feet in length. Moreover, the GFX-2 now features an all-digital switching backbone and an updated electronics system, allowing customers to control their boat via a touch screen on a 24-inch multifunction display. The GFX-2 center console boats also benefit from a complete redesign, with improved upholstery, all-new ergonomics, increased fuel capacity, updated color options, and streamlined console framing. While all those upgrades now come standard on every new GFX-2 boat, Twin Vee also offers new options that integrate the latest innovations in navigation, fishing, and water sports. The 26-foot 260 GFX-2 will be entering production next month, with the 280 and 340 GFX-2 to follow in June. The all-new 240 GFX-2 will then enter production in July. They will join the 400 GFX-2, which was upgraded earlier this year. Twin Vee plans to showcase the first 260 GFX-2 during its annual dealer meeting on May 20th in West Palm Beach.

08:50 EDT Catheter Precision expects cash flow break even by end of calendar year - "This new group is expected to focus on both product lines, VIVO and LockeT", continued CEO David Jenkins. "Over the last year, we have been primarily working on getting VIVO into key accounts and accumulating clinical data on LockeT. This expansion demonstrates a new effort toward commercialization of both product lines. With a 90% gross margin on both products, we anticipate that the expected increase in revenue will bring about cash flow break even by the end of this calendar year."

08:49 EDT Mega Matrix falls 9% to $2.55 after White Diamond short report

08:47 EDT Orbit International reports Q1 consolidated bookings $12.7M - Orbit International announced that consolidated bookings for the first quarter of 2024 were approximately $12,700,000. Deliveries for these orders have already commenced and are expected to continue through the first quarter of 2026. Bookings for the quarter were attributable to strong bookings from both the Company's Electronics Group, which include its Simulator Products Solutions LLC subsidiary, and its Power Group. Bookings for the OEG, exclusive of SPS, were in excess of $4,500,000 for the first quarter and were highlighted by two previously announced awards totaling approximately $3,150,000 from major defense contractors for units used on major military aircraft programs for the U.S. Navy. Bookings for the OPG include a significant order for its VPX power supplies as well as a large order for a commercial power supply used on a military program. The combined orders totaled approximately $2,300,000. Orders for SPS for the first quarter include several follow-on and new awards totaling approximately $4,800,000, highlighted by two orders received during the quarter from a defense contractor in excess of $1,700,000.

08:45 EDT Janover says organic website traffic increases 73% in 2023 - Janover announced that organic website traffic increased more than 70% in 2023 compared to 2022 and also reported that it achieved over 100 million organic impressions on google for the year ended December 31, 2023. Organic traffic is the number of website visitors that come from unpaid search engine results. Organic impressions represent the instances, as reported by Google, when a user sees a link to the website while conducting a search without the aid of paid advertising. "We are pleased to have surpassed the 100 million impression mark in a calendar year. It's a testament to the anti-fragility of a marketplace and how market dislocations can add value to corners of the business," said Blake Janover, Chairman, and CEO of Janover Inc. "Since inception, we've taken well over $200 billion in commercial loan applications, almost entirely through organic traffic from search engine optimization, which drives inbound applications at zero incremental cost to us. Moreover, we had more than 100 million impressions on Google. The increase in organic website traffic and organic impressions are a direct result of our successful SEO efforts and strategies as well as the nature of our business, which over the long term, we expect to benefit from market dislocations. These 100 million impressions contribute to our brand and its subsequent visibility which we believe will ultimately improve conversion rates as well. We're modernizing financial services for entrepreneurial commercial real estate and small business owners and the first step of that process happens online. We're proud of what we're building," concluded Mr. Janover.

08:43 EDT eFfector sees no 'obvious' path forward for tomivosertib development in NSCLC - eFFECTOR Therapeutics announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer NSCLC with PD-L1 greater than or equal to50%. Based on 36 events, the hazard ratio for progression free survival with PFS, the primary endpoint of the study, using a stratified Cox proportional hazards model was 0.62 in favor of tomivosertib. The two-sided p value for PFS, based on a stratified log rank test, was 0.21, which did not meet the pre-specified threshold of pless than or equal to0.2. The median PFS was 13.0 weeks in the tomivosertib plus pembrolizumab arm and 11.7 weeks in the placebo plus pembrolizumab arm, respectively. Overall survival results remain immature, however no trend favoring tomivosertib was observed. There were 67% Grade 3 or higher treatment emergent adverse events in the tomivosertib plus pembrolizumab arm versus 37% in the placebo plus pembrolizumab arm. "While there was evidence of modest tomivosertib activity in the trial, based on the totality of the data currently available we do not see an obvious path forward to continue developing tomivosertib in frontline NSCLC," said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. "We sincerely appreciate the contributions of all the patients, their families, and trial site professionals who contributed to the execution of the trial. We will continue to analyze trial data and hope to present our findings at a future medical conference." r

08:42 EDT Marathon Digital produces 894 bitcoin in March - "Throughout the first quarter, our Bitcoin production has been impacted by unexpected equipment failures, transmission line maintenance, and higher than anticipated weather-related curtailment across multiple sites," said Fred Thiel, Marathon's chairman and CEO. "After maintenance issues at Garden City were addressed, the site experienced higher than anticipated curtailment in March. At Granbury, McCamey, and Ellendale, we are continuing to work through transformer issues that have reduced capacity at those sites below historical norms. While the site in Ellendale was briefly recovered and re-energized at the end of February, it had to be brought back down due to the persistence of quality issues with the transformers sourced at the site. The demonstrated complexity of re-energizing Ellendale, along with the latest information and recent progress, indicates that capacity at this site is likely to be gradually increased over the coming months. Applied Digital is using its best commercially reasonable efforts to shorten and pull up the energization timeline. While our hosting provider continues to swap in newly acquired transformers and bring capacity at Ellendale back online, we have continued to focus on optimizing our performance at other sites. In March, we began relocating miners from Ellendale to take advantage of the additional capacity we recently acquired through our strategic acquisitions of sites in Texas and Nebraska. We are also preparing to transition part of Granbury to immersion to optimize performance. Despite the challenges, we increased our average operational hash rate by 4% in March to 18.3 exahash, and we increased our bitcoin production 7% to 894 bitcoin. We now have 17,381 BTC on our balance sheet, and our combined cash and bitcoin holdings are approximately $1.6 billion. As Ellendale is gradually brought back online, we intend to further develop our Bitcoin mining portfolio, which is growing to approximately 1.1 gigawatts of capacity diversified across 11 sites on three continents, and leveraging our recently announced technology innovations, like our two-phase immersion cooling system, to optimize performance and expand our position as a leader in converting energy into economic value."

08:41 EDT Ford updates EV, hybrid plans, readies manufacturing plants - Ford Motor Company said it is retiming the launch of upcoming electric vehicles at its Oakville, Ontario, assembly plant while continuing to build out an advanced industrial system to produce its next-generation electric vehicles, including greenfield construction and conversion of existing assembly plants. The company continues to invest in a broad set of EV programs as it works to build a full EV line-up. These initiatives support the development of a differentiated and profitably growing EV business over time while Ford serves customers with the right mix of gas, hybrid and electric vehicles based on demand today. In parallel, Ford is expanding its hybrid electric vehicle offerings. By the end of the decade, the company expects to offer hybrid powertrains across its entire Ford Blue lineup in North America. In the first quarter of 2024, Ford's electric vehicle sales increased by 86% and hybrid sales rose 42% versus a year ago. Additionally: Equipment installation is underway at the Tennessee Electric Vehicle Center assembly plant at BlueOval City, which aims to begin customer deliveries of Ford's next-generation electric truck in 2026; Expansion progresses at Ohio Assembly Plant in Avon Lake, to produce an all-new electric commercial vehicle for Ford Pro customers beginning mid-decade; construction progressing at BlueOval Battery Park Michigan, and BlueOval SK joint venture battery plants in Tennessee and Kentucky; Ford reiterates commitment to its Oakville, Ontario, assembly plant as the company retimes the launch of its all-new three-row electric vehicles to 2027; Design work continues on future EVs, including a flexible small and affordable EV platform by a skunkworks team in California.

08:40 EDT Bitdeer mines 294 bitcoin in March - Linghui Kong, Chief Business Officer of Bitdeer, commented, "During the month of March, we executed on our core operations and set the stage to drive the long-term growth of our business, most notably by announcing a plan to expand our self-mining hash rate by approximately 3.4 EH/s by the end of 2024. We intend to achieve this by installing our own SEALMINER A1 machines at our mining datacenters in Rockdale, Texas, U.S.A., and in Norway. Several similar expansions for our mining hash rate are expected to follow in subsequent quarters until the end of 2025. We mined 294 Bitcoins in total during March, representing an increase of 2.4% from last month. As we previously announced, our self-mining operations at our Gedu datacenter experienced curtailment during the first quarter due to seasonally higher electricity prices. However, we have secured a price of approximately $0.0425 per kWh for the Gedu datacenter for the remainder of the year starting on April 1, 2024. With this electricity price in place, we are currently maintaining stable operations with lower costs at our Gedu datacenter. On the AI cloud service front, we completed the deployment and testing of our NVIDIA DGX SuperPOD H100 system. We successfully met our target deployment deadline, establishing ourselves as one of the first providers of the NVIDIA DGX SuperPOD H100 service within Asia. On the infrastructure front, we commenced construction during March of a 500MW datacenter in Jigmeling, Bhutan. At this stage, we have committed to the construction of a substation at the site and have begun ground leveling work, and we anticipate the site becoming operational around the middle of 2025. We also continued to make progress in the construction of our 221MW datacenter in Ohio, United States, and our 175MW immersion cooling datacenter at our mining facility in Tydal, Norway. Both the Ohio datacenter and the Tydal datacenter are expected to be completed by 2025."

08:38 EDT HeartCore Enterprises forms AI software development division - HeartCore Enterprises has formed a new division focused on developing Artificial Intelligence software solutions for new and existing clients across the United States and Japan. Driven by the surging demand for AI solutions, HeartCore, alongside its U.S.-based subsidiary Sigmaways, has established a dedicated AI software development division, distinguished by their industry and technical prowess. The team comprises four recently recruited engineers from India, complemented by seasoned members from Sigmaways' U.S. development division. Together, they will spearhead the development and integration of cutting-edge AI-enhanced technologies, expanding the company's collective offerings to existing and prospective customers across diverse sectors. HeartCore's AI development division has commenced work on its first AI solution prototype, an investor readiness evaluator for startups seeking clear feedback and assessment on their company's offerings and strengths to attract investment in Pre-Seed, Seed, or Series A rounds.

08:38 EDT Arbutus 'pleased' with claim construction ruling in patent infringement suit - Arbutus Biopharma (ABUS) issued the following statement regarding the claim construction ruling of the U.S. District Court for the District of Delaware in the lawsuit brought by Arbutus and its licensee Genevant Sciences against Moderna, (MRNA) and a Moderna affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna's vaccine for COVID-19. The following summarizes the Court's Opinion: Composition of Total Lipid: The Court agreed with Plaintiffs' position that the claimed molar percentage ranges can be met by any particle and is not limited to "finished" particles that are not subjected to further process steps. The Court agreed with Plaintiffs' position that the claimed mol. % ranges include standard variation based on the number of significant figures recited in the claim. Cationic Lipid with Protonatable Tertiary Amine: The Court agreed with Plaintiffs' position that there is no limitation as to the mol. % of the claimed cationic lipid. Encapsulation of mRNA: The Court held that "wherein at least 70% / at least 80% / about 90% of the mRNA in the formulation is fully encapsulated in the lipid vesicles" means "wherein at least 70% / at least 80% / about 90% of the mRNA is fully, as distinct from partially, contained inside the lipid vesicles". "We are pleased with how the Court construed the disputed claim terms," said Michael J. McElhaugh, Interim President and CEO of Arbutus Biopharma. "We remain committed to protecting and defending our intellectual property and look forward to the next steps in the litigation."

08:36 EDT Rayliant Global partners with SMDAM to launch RAYJ - Rayliant Global Advisors announced that it has partnered with Sumitomo Mitsui DS Asset Management, SMDAM to launch the Rayliant SMDAM Japan Equity ETF, RAYJ. "This ETF partnership allows us to share our longstanding active Japanese equity expertise with a groundbreaking ETF provider and exceptional quantitative asset manager in Rayliant," said Takashi Saruta, CEO of Sumitomo Mitsui DS Asset Management. "Dr. Hsu and his team are working to create the most effective new ETF tools for those looking to invest in international markets, and we are proud to offer of our fundamental Japanese equities expertise to contribute to the strength of the Rayliant SMDAM Japan Equity ETF."

08:35 EDT TC Biopharm executes non-binding LOI for acquisition of NK platform technologies - TC BioPharm announced the execution of a non-binding letter of intent, or LOI, as part of its M&A strategy aimed at expanding its therapeutic platform and leveraging NK - natural killer - cells in treating both solid tumors and other indications. The target asset acquisition covers the proprietary manufacturing process of two allogeneic CAR-NK therapeutics, both of which TCB believes are valuable as monotherapies as well as in conjunction with TCB-008 in the future. TCB sees substantial synergies in this potential acquisition, both in clinical therapeutic terms of TCB-008 in combination with the CAR-NK assets, as well as leveraging the existing expertise and human capital of TCB to further advance and refine the manufacturing process while bringing in additional CAR expertise to advance multiple platforms. TC BioPharm has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement. Upon execution of the definitive agreements, the completion of the transaction will be subject to, among other matters, satisfaction of the conditions negotiated therein, the company having secured adequate financing, and receipt of all third party approvals, licenses, consents, and clearances, as and when applicable.

08:34 EDT Clean Harbors launches 'Total PFAS Solution' - Clean Harbors introduced its "Total PFAS Solution" to address all the needs of customers related to PFAS, which are commonly referred to as forever chemicals. Clean Harbors' Total PFAS Solution is the industry's first and only one-stop-shop consisting of eight core elements and providing customers with a range of services from analysis to remediation to disposal.

08:31 EDT ECD Automotive Design to acquire Brand New Muscle Car assets - ECD Auto Design has signed an agreement to acquire certain assets from Brand New Muscle Car, a builder of classic American muscle cars for restricted stock of ECD to be valued at $1.5M on the date of issuance. Brand New Muscle Car, founded in 2005 and headquartered in Broken Arrow, OK, is the from scratch restorer of classic American muscle cars designed with new parts.

08:30 EDT Sidus Space offers spacecraft Mission Control Center - Sidus Space unveils its Mission Control Center as an additional revenue stream within the Company's Space-Based Data Solutions business unit. Sidus' products and services are offered through its four business units: Space and Defense Hardware Manufacturing, Satellite Manufacturing and Payload Integration, Space-Based Data Solutions, and AI/ML Products and Services. The MCC presents a unique service offering to monitor and support spacecraft missions and generate additional revenue from commercial customers. "We are excited to offer this capability to commercial customers to provide a much-needed service to the Space ecosystem," said Carol Craig, CEO. "This specialized service adds another revenue stream to our heritage-based space capabilities which will result in added value for our shareholders."

08:28 EDT NMI Holdings announces enhanced integration with PMI Rate Pro - National Mortgage Insurance Corporation announced an enhanced integration with PMI Rate Pro, a provider of mortgage insurance pricing technology. Leveraging PMI Rate Pro's new single API solution, the integration will help lenders and borrowers save time and money when ordering mortgage insurance from National MI. PMI Rate Pro's pioneering platform streamlines the Private Mortgage Insurance process for lenders, delivering a higher level of efficiency and transparency. The technology company recently enhanced its platform with a single API solution that offers quoting, risk-allocation and ordering functionalities for lenders and mortgage software providers. The API integrates easily with popular loan origination systems, pricing engines, and point of sale technologies, requiring very little development effort to set up.

08:25 EDT eFFECTOR Therapeutics trading halted, news pending

08:24 EDT Primoris targets 2024-2026 revenue growth of 4%-6% - As part of its 2024 Investor Day presentation yesterday, the company also forecast adjusted EBITDA growth at 9%-12% and operating cash flow margin of 4%-5%. Reference Link

08:23 EDT Westwood One to broadcast NCAA Division I Men's Final Four in Spanish - Cumulus Media's Westwood One will provide exclusive audio coverage of the NCAA Men's Final Four and national championship game in Spanish for the seventh consecutive tournament, presented by Werner Ladder, the official ladder of the NCAA Men's and Women's Basketball Championships. Westwood One's Spanish-language broadcasts will kick off at 6 p.m. ET on Saturday, April 6 with the 2024 Men's Final Four live from Phoenix, when the NC State Wolfpack takes on the Purdue Boilermakers. The second national semifinal, between the Alabama Crimson Tide and the defending champion UConn Huskies, will begin 40 minutes after the conclusion of the first game. Spanish-language coverage will continue with the national championship game on Monday, April 8 at 9:00 p.m. ET. Rafael Hernandez Brito will once again serve as the play-by-play announcer, his seventh time with the network, while former All-American point guard Greivis Vasquez will return as analyst for the sixth time. For the fourth time, former Puerto Rican National Basketball Team coach Carlos Morales will host the broadcasts.

08:20 EDT Acumen teams with Lonza for advancement of sabirnetug to treat AD - Acumen Pharmaceuticals (ABOS) has signed a collaboration agreement with Lonza (LZAGY), "a global partner to the pharmaceutical, biotech and nutraceutical markets." The agreement covers the manufacture of sabirnetug ACU193 , an antibody targeting toxic soluble AbetaOs for the treatment of AD, for clinical development and commercialization, if approved. Under the terms of the agreement, Lonza will manufacture the sabirnetug drug substance at its next-generation, manufacturing facility in Portsmouth, New Hampshire equipped with 2,000L single-use bioreactors. Acumen will leverage Lonza's regulatory expertise, extensive experience in antibody manufacturing, and global manufacturing network from 2,000L to 20,000L. James Doherty, President and Chief Development Officer, Acumen Pharmaceuticals, added: "As we progress into Phase 2 clinical development of sabirnetug as a potentially best-in-class treatment for early AD, we are acutely aware that patients and their families are in urgent need of safe, effective treatment options for this devastating disease. Partnering with Lonza is a critical step to ensure broader access to next-generation AD therapies."

08:16 EDT Replimune Group announces inducement grants under Nasdaq listing rule - Replimune Group announced the grant of inducement equity awards to Carolyn Trott, the Company's newly appointed Senior Vice President, Quality Assurance. The inducement awards consist of a non-qualified stock option to purchase 75,000 shares of the Company's common stock and restricted stock units representing 50,000 shares of the Company's common stock. The option has an exercise price of $7.73 per share, which is equal to the closing price of the Company's common stock on the date of grant. The option has a 10-year term and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the remainder vesting monthly for three years thereafter. The restricted stock units vest in approximately four equal annual installments beginning on May 15, 2025. The inducement awards were granted under the Company's previously approved Employment Commencement Incentive Plan and were approved by the compensation committee of the Company's board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4). While the inducement awards were granted outside of Replimune's 2018 Equity Incentive Plan, the awards will have terms and conditions consistent with those set forth under the plan.

08:14 EDT American Oncology Network teams with Central Georgia Cancer Care - Central Georgia Cancer Care is excited to announce their partnership with the American Oncology Network AON one of the nation's fastest-growing networks of community-based oncology practices, to further strengthen their patient care and services by utilizing the network's vast resources and expertise. Central Georgia Cancer Care is a nationally recognized independent oncology practice known for providing personalized care close to home. They treat patients diagnosed with cancers and blood disorders at their clinics in Macon and Warner Robins. Their team includes four Board-certified medical oncologists; a supportive care physician Board-certified in hospice, palliative medicine, physical medicine and rehabilitation; and 11 advanced practice providers. Additionally, the practice is dedicated to creating opportunities for clinical trial participation and establishing relationships with research hospitals to ensure patients have access to cutting-edge care and therapies in Central and South Georgia.

08:13 EDT Paragon 28 announces CFO Deitsch to depart, Wright named interim CFO - Paragon 28 announced that Stephen Deitsch, Chief Financial Officer, CFO, has notified the Company of his intent to pursue an opportunity with OrganOx Limited. Deitsch will depart from the Company on April 5, 2024. The Company has formed a sub-committee of its Board of Directors and has engaged an executive search firm to assist in identifying a permanent successor. The Company concurrently announced the appointment of Kristina Wright as Interim CFO, effective April 3, 2024. Wright has been a member of the Board of Directors since 2021 and currently serves as Chair of the Company's Audit Committee and as a member of the Nominating and Corporate Governance Committee of Paragon 28.

08:12 EDT Advent Technologies signs strategic JDA with Siemens Energy - Advent Technologies (ADN) announces that its wholly owned subsidiary, Advent Technologies A/S, has signed a Joint Development Agreement, JDA, with Siemens Energy (SMNEY). The newly signed JDA outlines the collaboration between Advent and Siemens Energy, combining Advent's HT-PEM fuel cell 50kW modules utilizing its innovative Ion-Pair membrane electrode assembly technology with Siemens Energy's electrification and automation solutions for hybrid and electric vessels. The goal is to develop an integrated 500kW High-Temperature Proton Exchange Membrane fuel cell solution for maritime applications and then evaluate to scale down/up the system to fit with market requirements from motor and Giga Yachts to ferries and container/commercial ships.

08:11 EDT Rigel Pharmaceuticals' olutasidenib shows efficacy in published AML study - Rigel Pharmaceuticals announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the Phase 2 study evaluating Rezlidhia - olutasidenib -, a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 or mIDH1, in patients with mIDH1 acute myeloid leukemia - AML - who were relapsed/refractory to prior venetoclax-based regimens. Olutasidenib alone or in combination with azacitidine demonstrated potential efficacy in patients with AML following failure of venetoclax combination therapy. Of the 18 patients with prior venetoclax treatment, 10 were relapsed, 6 were refractory, and 2 had complete remission with incomplete hematologic recovery to a venetoclax combination. Of the 16 R/R patients, 7 achieved a composite complete remission, 4 achieved complete remission, and 1 achieved CR with partial hematologic recovery. Both patients with CRi at study entry achieved CR. Red blood cell and platelet transfusion independence was achieved in 2/12 and 2/7 transfusion-dependent R/R patients at baseline, respectively. Safety was consistent with the overall profile of olutasidenib. The paper was published online in Leukemia & Lymphoma.

08:10 EDT Aiven achieves sustainability goals with Thoughtworks - Thoughtworks and Aiven are tackling the challenge of lowering the CO2 emissions of the IT industry. Together, they conducted an internal sustainability assessment for Aiven and are helping Aiven customers manage their environmental impact, all in strong support of open-source. As a founding member of the non-profit Green Software Foundation, Thoughtworks brings deep expertise in building robust ecosystems for sustainable software development. One important achievement was developing the open source solution Cloud Carbon Footprint, a tool Thoughtworks designed to calculate CO2 emissions.

08:08 EDT Rocky Brands publishes inaugural ESG report - Rocky Brands announced the publication of its inaugural Environmental, Social and Governance, ESG, Report. The ESG Report illustrates how Rocky Brands drives corporate responsibility and serves its community through avenues of product innovation, philanthropy and responsible business practices. "We have taken steps to underscore our impact in our supply chains and the people who make our products," said Jason Brooks, CEO of Rocky Brands. "Our focus on ESG highlights our long-term value creation for our stakeholders, showcases our commitment to creating a positive impact in our community and solidifies our strategic ambition to unlock value creating sustainability."

08:08 EDT Nikola produced 43 Class 8 Nikola hydrogen fuel cell EVs in Q1 - It was a productive Q1 for Nikola via the HYLA brand, as the company produced 43 and wholesaled 40 Class 8 Nikola hydrogen fuel cell electric vehicles. In addition, the Nikola team has commenced the return process for the BEV "2.0" trucks to customers. "We are on track for a successful 2024 by continuing the momentum set in 2023," said Nikola CEO Steve Girsky. "It's about more than just setting goals. It's about following through on our commitments. This includes not only the production and sale of our hydrogen fuel cell electric trucks but also the start of returns for our battery-electric trucks to customers." All trucks wholesaled to Nikola dealers are destined for end customers. The three remaining hydrogen fuel cell electric trucks in finished goods inventory at the end of the quarter have already been allocated and will be delivered in early April.

08:07 EDT Brookfield Asset Management partners with two Upper Midwest capital firms - Brookfield Asset Management announced a strategic partnership with Soundcore Capital Partners and its commercial paving platform, Heartland Paving Partners. The investment is to accelerate the platform's growth as it pursues further consolidation in the Upper Midwest market. The transaction marks Brookfield's first investment through its private equity sponsor solutions strategy, which focuses on providing bespoke solutions to mid-market buyout sponsors seeking secondary and growth capital for high performing assets. Soundcore acquired the initial Heartland investment in July 2022 and has since completed several acquisitions, expanding operations to become a regional provider of commercial paving services. The company partners with property owners throughout the lifecycle of their parking and other paved surface assets. Financial terms of the transaction were not disclosed.

08:05 EDT Yunji receives approval to transfer to Nasdaq Capital Market - Yunji announced that on April 3, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC approved the company's request to transfer the listing of the company's American Depositary Shares from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer is expected to take effect at the opening of business on April 5. The transfer of the company's listing to the Nasdaq Capital Market is not expected to have any impact on trading in the company's ADSs. The company's ADSs will continue to trade uninterruptedly under the symbol "YJ." The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, and companies on the Nasdaq Capital Market must meet certain financial and corporate governance requirements to qualify for continued listing.

08:04 EDT Vuzix receives additional orders from two aerospace and defense firms - Vuzix has received new additional orders from two aerospace and defense firms to further develop and deliver waveguide-based display solutions in 2024. The first, a new order from a global Tier-1 aerospace and defense firm, involves the development of new head mounted display technology for military aircraft. The customized HMD waveguide and HD display engine development program with this customer has continued to expand and move toward eventual production. Vuzix has previously completed multiple stages of product development and refinement with this partner. Vuzix has also received a new follow-on order for further development of a lightweight heads-up display replacement for technologies previously supplied by a China-based company. This order was received from a US-based company that is a leader in technologically advanced and intelligent solutions for the global aerospace and defense industry.

08:04 EDT NV5 Global in pact to acquire GIS Solutions, no terms disclosed - NV5 Global, announced that it has reached an agreement to acquire GIS Solutions a full range provider of enterprise geographic information system GIS technologies and services including GIS application development, cloud-based database design, data science, and project management. GIS Solutions supports state departments of transportation and utilities by developing solutions that monitor asset management, expedite efficient service delivery, and deliver real-time mapping and incident reporting. The acquisition was made with a combination of cash and stock and will be immediately accretive to NV5's earnings."Tech-enabled services, such as geospatial solutions, have grown as a percentage of NV5's revenue as we focus on services with higher margins and more rapid scalability than traditional surveying services, and we are pleased to add GIS Solutions to the NV5 organization," said Dickerson Wright, PE, Executive Chairman of NV5. "We will continue to identify and pursue opportunities in geospatial and other tech-enabled service categories to drive margin expansion and organic growth throughout NV5." "We are excited to join the NV5 team, and we look forward to the growth opportunities available to our valued employees as part of the nation's largest geospatial data analytics firm," said Jim Conlon, President of GIS Solutions.

08:04 EDT Digimarc appoints Karamanos as Chief Legal Officer - Digimarc announced that former ZipHQ Chief Legal Officer and seasoned deal strategy and operations leader George Karamanos has joined the company as Chief Legal Officer, CLO. Karamanos brings proven expertise in supporting the hyper-scale growth of world-class enterprise software businesses.

08:02 EDT Allurion Technologies expands Virtual Care Suite to the U.S. - Allurion Technologies announced the commercial availability of its comprehensive Virtual Care Suite, VCS, in the United States. Already in use by thousands of providers in over 50 countries, the VCS is a dynamic weight-loss management suite powered by artificial intelligence featuring remote patient monitoring, telehealth and care team collaboration all under the one digital umbrella, designed to maximize patient outcomes and satisfaction. "After witnessing the profound impact our technology has had globally, we are thrilled to launch the VCS in the United States. Our team is incredibly excited to provide US clinics with digital solutions to help them significantly bolster both clinical outcomes and patient experience for all weight-loss treatments, including anti-obesity medications and bariatric surgery, especially as GLP-1 usage surges," said Brian Conyer, Vice President of Digital Health. "Our research indicates that the VCS has already enhanced patient results, engagement, and satisfaction. Clinics with the highest VCS usage achieve an additional 11% weight loss1, with 16% more patients reaching their goals1, and a 17% increase in Net Promoter Score (NPS)2."

08:02 EDT Manitex announces first deliveries on new articulated truck mounted crane - Manitex International announced the first deliveries of the recently launched PM 70.5 SP articulated truck mounted crane. The new 70.5 SP articulated crane is the latest enhancement to PM Group's 65 series of articulated cranes with applications for the global market. The 70.5 SP is multi-industry capable, serving heavy industrial, infrastructure, concrete and general construction. The new offering from PM Group is initially being sold in Europe and will be available in North America next year. "A key component of our Elevating Excellence strategy is to expand our distribution of PM Group products in North America, and the PM 70.5 SP is the first of several new product offerings that will be integral to us achieving this goal," stated Michael Coffey, Chief Executive Officer of Manitex. "This innovative new product will enable us to expand our addressable market and should contribute to further market penetration and service into North America."

07:58 EDT ZyVersa Therapeutics highlights publication on NLRP3 inflammasome inhibition - ZyVersa Therapeutics highlights data from a peer-reviewed article published in Biochemical and Biophysical Research Communications. This article demonstrates that NLRP3 inhibition results in improved glucose tolerance and markedly smaller and more stable atherosclerotic lesions in a diabetic mouse model. In the paper titled, "High glucose levels accelerate atherosclerosis via NLRP3-IL/ MAPK/ NF-B-related inflammation pathways," the authors evaluated serum and coronary artery tissues from patients with coronary artery disease, with and without diabetes and they conducted a study in diabetic mouse models. Key findings include: Patients with comorbid CAD and diabetes had higher serum levels and expression of NLRP3 in their coronary arteries, and increased serum levels of IL-1beta and IL-6 than those with CAD only. Diabetic mouse models showed a significantly higher atherosclerotic plaque/vessel area ratio than non-diabetic mice, which was markedly reduced with NLRP3 inhibition and the resulting reduction in levels of proinflammatory cytokines and inflammation. The authors concluded, "Our research offers new understanding of the pathological mechanisms of diabetes-accelerated AS and provide a novel and promising target for treating diabetes-accelerated AS."

07:54 EDT Iris Energy mines 353 bitcoin in March - March operations: Average operating hashrate of 7.1 EH/s; now expanded to 8 EH/s; Monthly mining revenue increased by 56% to $23.7m, due to increased hashrate and higher Bitcoin price; 2024 expansion to 20 EH/s, now fully funded; H1 2024 10 EH/s - 8 EH/s operating, remaining 2 EH/s to be commissioned; H2 2024 20 EH/s - 10 EH/s of new miners secured; 20 EH/s generates ~$269m of annualized hardware profit.

07:52 EDT HUB Security acquires QPoint Technologies, terms not disclosed - HUB Cyber Security announced the acquisition for cash of Qpoint Technologies. Following this acquisition HUB holds 100% of QPoint. This acquisition is strategically aligned with HUB's mission to establish a leading global secure data fabric ecosystem. QPoint, boasting a diverse customer base of over 100 renowned brand clients, including partnerships with Rafael Advanced Defense Systems, the developer of the "Iron Dome", the Israel Airport Authority and the Ministry of Defense of Israel. Established in 2009, QPoint comprises five subsidiaries and provides solutions and consulting across various verticals, including innovative data management and security solutions. The strategic integration enhances HUB's capabilities in safeguarding sensitive information across various sectors. QPoint has expertise in software engineering, testing, cybersecurity, ICT, web, mobile, project management, and complex integration processes, bringing invaluable additions to HUB portfolio and expanding market reach, revenue stability and customer support. There is a significant cross-selling opportunity between QPoint and HUB's expanded offerings, with customers spanning the healthcare, government, energy, defense, and financial sectors. Enhancing the value of this acquisition further, QPoint has exhibited robust financial health, boasting an annual revenue in FY23 of about $26 million. In addition, QPoint showcases remarkable growth metrics, with a year-over-year (YoY) customer growth rate surpassing 80%.

07:45 EDT ARway introduces AR navigation with Generative AI ChatGPT 4D avatars - ARway.ai announced another paid partner deal with AVR Labs, a company based in the United Arab Emirates specializing in XR technologies. AVR Labs will be a recognized partner of ARway in the Gulf Region, increasing ARway's distribution channel, as they have 100+ projects from paying customers deployed across 20 countries around the globe. This collaboration is set to revolutionize AR navigation by integrating generative AI 3D/AR avatars with conversational immersive interaction capabilities, powered by ARway's advanced platform and AVR Labs' innovative solutions.The partnership aims to integrate these AR GPTs into the ARway platform, enhancing AR navigation experiences with the addition of conversational AI avatars. These avatars, accessible via a visual marker scan, will act as interactive tour guides, offering personalized navigation assistance and enriching user interactions within AR spaces.

07:42 EDT Sonoma Pharmaceuticals reports publication highlighting Microdox potential - Sonoma Pharmaceuticals reported a recent publication in the journal Neurourology and Urodynamics highlighting the potential for Microdox in the management of urinary tract infections, or UTIs, in children with neurogenic or non-neurogenic bladder dysfunction. Microdox is a super-oxidized solution based on Sonoma's patented Microcyn technology intended to treat and prevent infections in the urinary tract and bladder. Microdox is licensed by the Therapeutic Goods Administration in Australia and by Medsafe in New Zealand for the prevention and treatment of UTIs, and is currently available in these countries through Sonoma's partner, Te Arai BioFarma Ltd. The publication in Neurourology and Urodynamics notes that children with a neurogenic bladder are at risk of developing recurrent urinary tract infections and long-term kidney failure, and that due to an altered lower urinary tract, children may be overtreated for simple bacteriuria, or undertreated for a potentially severe urinary tract infection. The authors posit that this risk necessitates new approaches to UTI management in these patients, who are high users of healthcare and for whom UTIs are a significant health burden. They propose that bladder irrigation with electrochemically activated solutions, such as Microdox, could be a powerful therapeutic option in children who require clean intermittent catheterization, with the potential to significantly approve outcomes for these patients. The article cites evidence from recent clinical trials that, in the short term at least, electrochemically activated solutions are effective in safely preventing asymptomatic bacteriuria with no adverse effects. The authors conclude that multi-center trials will be required to establish potential long-term preventative effects.

07:39 EDT Trinity Biotech provides update on execution of key initiatives - The company said, "Optimization of our existing Diabetes business: Launch of the Improved Column System: Our programme to develop an improved, backward compatible Diabetes HbA1c column system is now completed. The results of this development programme have exceeded expectations, with our new column system now delivering up to 4 times the number of injections compared to the existing product. As planned, we are now executing on the commercial launch of these new products. In-house manufacturing process: Our revised in-house manufacturing process of our key Diabetes HbA1c consumable began in Q4, 2023 as planned, and in Q1, 2024 we ceased to order any further product from our outsourced supplier. We remain on track to deliver approximately $4 million of annualised recurring cost savings from this and our ongoing Diabetes business supply chain optimisation initiatives, based on expected production volumes, and we believe that these changes will allow us to deliver an increasingly cost competitive Diabetes HbA1c solution, putting us in a stronger position to grow market share over time. TrinScreen HIV update: Earlier this week we received a purchase order for an additional 2 million TrinScreen HIV tests for the Kenya market and expect to deliver these in Q2, 2024. Additionally, in Q1, 2024 we successfully scaled manufacturing of our new rapid HIV screening test, TrinScreen HIV and have manufactured all 2.5 million tests from the initial Kenya purchase order. The ability to deliver such a significant increase in production capacity was an important demonstration to our stakeholders of our execution capabilities and our commitment to the new HIV testing algorithm adopted by the Kenyan Ministry of Health that established TrinScreen HIV as the screening test under World Health Organisation guidelines. The Kenyan HIV screening programme is one of the largest in Africa, with up to an estimated 10 million screening tests annually."

07:36 EDT Zimmer Biomet becomes official medical device partner of U.S. pickleball - Zimmer Biomet announced partnerships with three top pickleball organizations in the U.S., becoming the first and only medical device partner for the sport of pickleball. As partners of Zimmer Biomet, the Association of Pickleball Players, Professional Pickleball Association and USA Pickleball, the National Governing Body for pickleball, have aligned with the company to alleviate pain and improve the quality of life for the 48.3 million pickleball players and spectators across the U.S. Zimmer Biomet is an official partner to the APP, PPA Tour, and USA Pickleball and will present interactive, onsite activations showcasing product innovations, and educating and raising awareness of the importance of joint health.

07:36 EDT Trinity Biotech to cease manufacturing at Kansas City plant - The company said, "At the Emerging Growth Investor Conference on March 7, 2024, our new management team announced a comprehensive transformation plan to deliver a step change in the financial performance of our existing business. Our transformation plan for the existing business has several key components that we believe are rapidly achievable, in most cases by mid-2025: We are reducing complexity and cost by consolidating our main manufacturing operations into a considerably smaller number of sites and also moving to an outsourced model for a significant amount of our less complex manufacturing activities. As part of this initiative, we are today announcing that we intend to cease manufacturing at our Kansas City manufacturing plant which currently serves our Haemoglobin business. We expect to have fully executed this change by the end of 2024 and expect this will deliver significant annualised savings. We are also significantly reducing the cost of goods of many of our products by changing suppliers and negotiating new deals with existing suppliers. This is an area we have already successfully executed on a number of cost saving initiatives, which we expect will deliver multi-million-dollar annualised savings. We are simplifying our internal operations, and optimising our business support function locations: Today we are announcing an initiative to move significant aspects of our business support functions to a lower cost and centralised location. We plan to complete this activity by Q4, 2024 and it is expected to deliver significant reductions to our existing SG&A costs, plus provide an efficient scalable business support platform to facilitate efficient growth in our wearable biosensor business."

07:34 EDT IM Cannabis, Avant Brands sign licensing agreement for German cannabis market - IM Cannabis (IMCC) and Avant Brands (AVTBF) signed an international trademark licensing agreement granting Adjupharm, IMC's German subsidiary, the exclusive right to launch the BLK MKT brand in the German medical cannabis market on their medical cannabis products. All such products will contain cannabis cultivated exclusively by Avant and subsequently exported to Germany. The collaboration between the two companies anticipates a positive outcome in the emerging German medical cannabis market, especially following the recent legalization by the government on April 1st. Avant's three largest cultivation facilities all hold ICANN-GAP and GACP certifications, positioning Avant to potentially distribute its premium cannabis flower into international markets.

07:33 EDT Cannabist Company announces partnership with Flower by Edie Parker - The Cannabist Company Holdings announced a partnership with Flower by Edie Parker, a leading female-founded and operated cannabis lifestyle brand. The Cannabist Company will introduce Flower by Edie Parker's premium cannabis products, including pre-rolls, vapes, and edibles, to six new markets: Arizona, California, Colorado, Delaware, Florida, and Virginia, and launch a new line of edibles in Illinois, Massachusetts, New Jersey and New York. The partnership will be the first to introduce Flower by Edie Parker, known for merging the worlds of fashion and flower, to customers and patients in these six new markets.

07:31 EDT Verastem announces inducement grants under Nasdaq listing rule - Verastem Oncology announced the grant of stock options to purchase 35,000 shares of its common stock to four new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to $11.73 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on April 1, 2024. The stock options to purchase 35,000 shares of common stock that were granted to the four new employees will vest at a rate of twenty-five percent on the one-year anniversary of each employee's date of hire, with the remaining shares vesting quarterly over the next three years in equal quarterly amounts, provided the employee continues to serve as an employee of or other service provider to Verastem Oncology on each such vesting date.

07:28 EDT AGF Management increases quarterly dividend to C$0.115 per share - On April 3, 2024, the Board of Directors of AGF Management Limited declared a dividend of C$0.115 per share on both the Class B Non-Voting shares and the Class A Voting common shares of the company. This dividend will be payable on April 24, 2024 to shareholders of record on April 11, 2024.

07:23 EDT CureVac announces Phase 2 interim data from influenza vaccine program - CureVac N.V. (CVAC) announced interim data from an ongoing Phase 2 part of the combined Phase 1/2 study of its seasonal influenza vaccine candidate, conducted in collaboration with GSK (GSK). The multivalent candidate was selected from a comprehensive Phase 1 part, which tested vaccine candidates with up to eight separate mRNA constructs per candidate. It was designed for broad antigen coverage, encoding antigens matched to all four WHO-recommended flu strains. Results from the planned interim analysis showed that the multivalent vaccine candidate using CureVac's proprietary second-generation mRNA backbone boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose. The vaccine candidate was shown to have an acceptable safety and tolerability profile, with the majority of solicited adverse events reported as either grade 1 or grade 2 within seven days of dosing. The results confirm previous findings that the platform elicits strong overall antibody titers at well-tolerated dose levels. Among younger and older adults, geometric mean titers generated by the vaccine candidate against influenza A strains numerically exceeded the geometric mean titers of the licensed comparator vaccines consistently across all tested dose levels. For influenza B strains geometric mean titers were lower than those elicited by the licensed comparator vaccines across both age groups and tested dose levels. Targeted optimizations to further improve immune responses against influenza B strains will be tested in an additional Phase 2 study. The Phase 2 dose-confirmation study assesses the reactogenicity, safety, and immunogenicity of different dose levels of a modified, multivalent vaccine candidate, encoding antigens matched to all four WHO-recommended flu strains. Reactogenicity, safety, and immunogenicity were assessed in 480 healthy younger adults aged 18 to 64 and 480 healthy older adults aged 65 to 85. In each age group, three different dose levels were tested in comparison to an age-appropriate, licensed comparator vaccine. For younger adults, immune responses were compared to a standard dose seasonal vaccine. For older adults, immune responses were compared to a high dose seasonal flu vaccine.

07:21 EDT Aclara Resources appoints Jose Augusto Palma as EVP - Aclara Resources announced the appointment of Jose Augusto Palma as Executive Vice President of the Company effective June 1, 2024. Jose Augusto will be a key member of the Company's leadership team and will be closely involved in all activities of strategic significance to the Company, including leading the development of relationships with public and private stakeholders and business partners, overseeing the permitting strategy, management of complex strategic issues and the development of corporate strategy and governance. Jose Augusto is a senior mining executive with over 17 years of experience in the sector and currently Vice President, Legal & Corporate Affairs of Hochschild Mining

07:17 EDT International Paper provides update on acquisition offer for DS Smith - International Paper (IP) provided an update on its possible offer for DS Smith (DITHF) pursuant to which International Paper would acquire the entire issued and to be issued share capital of DS Smith. International Paper stated that significant progress has been made in reciprocal due diligence as facilitated by the DS Smith Board and Management, and provided shareholders with more detail on the type and quantum of synergies it believes would arise from the combination. Due diligence has confirmed International Paper's belief that the combination will significantly strengthen the combined packaging business and customer offerings - with packaging representing 84% of International Paper's current sales, approximately $1.5B of which is driven from European sales. Directors believe that the combined International Paper and DS Smith group can deliver at least $514M of pre-tax cash synergies on an annual run-rate basis by the end of the fourth year following completion of the combination. International Paper anticipates that the total costs to achieve the synergies would be approximately $370M. International Paper expects that approximately 33% of the synergies outlined above would be achieved by the end of the first year following completion, with approximately 66% and 95% achieved by the end of the second and third years following completion, all on a run-rate basis, respectively. Aside from the one off costs referred to above, the International Paper Board does not expect any material dis synergies to arise as a direct result of the combination. The combination is expected to increase International Paper's margins through synergies and to be immediately EPS accretive. Return on invested capital from the Combination is expected to exceed International Paper's weighted average cost of capital by the end of the third year following completion. DS Smith's North American manufacturing locations and International Paper's European manufacturing locations would continue their respective operations. Any new International Paper shares issued to DS Smith shareholders will be authorised for primary listing on the NYSE subject to official notice of issuance and International Paper intends to seek a secondary listing of its shares on the London Stock Exchange. International Paper is required, by not later than 5.00 p.m. London time on 23 April to either announce a firm intention to make an offer for DS Smith or announce that it does not intend to make an offer.

07:16 EDT NextCure appoints Rakesh Dixit to Scientific Advisory Board - NextCure announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board. Dixit currently serves as President and CEO of Bionavigen, a biopharmaceutical company specializing in consulting and drug hunting for biologic, cell and gene therapy and small molecule drug development. He is also President and CSO of Regio Biosciences, an AstraZeneca spinoff company.

07:13 EDT Mayfair Gold responds to Muddy Waters' 'misleading and inaccurate' statements - Mayfair Gold responded to a letter to shareholders released by Muddy Waters Capital on April 2, 2024, confirming that Muddy Waters has requisitioned a meeting of shareholders for the purpose of reconstituting the Company's board of directors. The company said, "The Company is reviewing the requisition and will respond within the timeframe set out in applicable legislation. In the meantime, there is no need for shareholders to take any action. The Company also wishes to set the record straight and correct misleading and inaccurate statements made by Muddy Waters in the Letter. Contrary to Muddy Waters' assertion that it hoped to resolve issues with the Company quickly, it has consistently refused to engage in a constructive dialogue with Mayfair. Instead, Muddy Waters has insisted that the Board immediately appoint its nominee Darren McLean as a director and chair, despite Mr. McLean never having served as a director or officer of a Canadian public company. When the Board indicated its willingness to consider Mr. McLean's candidacy as part of a comprehensive and proactive process to identify suitable candidates for board recruitment, Muddy Waters refused. Muddy Waters did not express any dissatisfaction or deterioration of trust in the Board until sending its March 14, 2024, demand that the Board immediately halt its recruitment process and instead appoint its nominee as Chair. The Letter also makes a number of unsubstantiated statements about compensation for directors and management which require clarification and context. The Company's option pool has not been "depleted" and sufficient options remain available under the Company's option plan to support any necessary additions to the Board or management team in the near term. Furthermore, approximately 90% of options under the Company's option plan were granted prior to Muddy Waters disclosing its investment in the Company. Mayfair's compensation has been supported by detailed research conducted by external consultants who have ranked the Company against a peer group of mineral exploration and development companies with a range of market capitalization, exchange listing, and enterprise value comparable to the Company. Contrary to statements made in the Letter, the Company's compensation has ranked well below that of its benchmark peer group. No shareholder other than Muddy Waters has expressed any concerns to the Board or management regarding the Company's compensation practices. An offer for a representative of Muddy Waters to meet with the Compensation Committee of the Board was declined. The Letter also refers to a founder of the Company being denied his nomination right to join the Board. That is not the case. To be clear, the Company will honor nomination rights held under the Board Nomination Rights Agreements held by two founders of the Company. The nomination rights can be exercised by holders of these rights when the Company provides notice of a shareholder meeting. The Company has not finalized the date of its 2024 annual general meeting, but will provide notice to nomination rights holders as soon as it does. There is no attempt by the current Board to entrench itself, and the Board and management welcome ongoing engagement with shareholders. Unfortunately, good faith efforts made by the Company to constructively address concerns raised by Muddy Waters have been rejected out of hand with no compromise suggested. The Board and management remain committed to good governance and value creation, and will continue to take actions that they believe are in the best interests of the Company. They remain focused on progressing Mayfair's flagship asset, the 100% controlled Fenn-Gib gold project in the Timmins region of Northern Ontario, as reflected by the recently announced initiation of a pre-feasibility study for the Fenn-Gib project in the Company's March 27, 2024, press release."

07:10 EDT ADC Therapeutics completes dose escalation in LOTIS-7 to treat r/r B-NHL - ADC Therapeutics announced the completion of dose escalation in LOTIS-7, a Phase 1b open-label clinical trial evaluating ZYNLONTA or oncastuximab tesirine-lpyl, in combination with bispecific antibodies glofitamab or mosunetuzumab in heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma, r/r B-NHL . "The early data from Part 1 of our LOTIS-7 trial highlight the potential combinability of ZYNLONTA with bispecifics in lymphoma patients," said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. "We look forward to the continued progression of this trial in 2L+ DLBCL patients.""With no or low grades of CRS and no ICANS observed among patients in Part 1 of the study, we believe LOTIS-7 demonstrates the potential for ZYNLONTA plus bispecifics to enable broader accessibility in community settings," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "Based upon the current data and coupled with the potential for additive or even synergistic efficacy with this combination, we continue to be excited about the opportunity to expand the use of ZYNLONTA in DLBCL in the future where there remains high unmet need."

07:08 EDT Cartesian announces new employment inducement grants - Cartesian Therapeutics announced the granting of inducement awards to four new employees. On April 1, 2024, the Company issued to each of these employees an option to purchase shares of the Company's common stock with an exercise price of $0.5601, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options are exercisable for an aggregate of 765,000 shares of the Company's common stock. Each of the four options was granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company's board of directors. The options each vest as to 25% on April 1, 2025, and then in three equal installments thereafter such that the option will be fully vested on April 1, 2028. The options each have a ten-year term.

07:07 EDT Adaptive Biotechnologies announces CFO transition - Earlier this week, the company stated: "Adaptive Biotechnologies announced that Tycho Peterson, chief financial officer (CFO), will be departing the company to pursue another opportunity. Kyle Piskel, who currently serves as the company's Principal Accounting Officer and has held various financial roles at Adaptive over the past 8 years, will succeed Tycho as full-time CFO. Kyle previously served as the company's Interim CFO from February to June 2022 and brings over 15 years of financial expertise to the role."

07:06 EDT Lantronix showcases campus PoE++ switches - Lantronix announced new managed gigabit PoE++ enterprise switches. The 8-port SM8TBT2SA, 24-port SM24TBT4SA and 24-port SM24TBT4XPA switches provide the ability to connect PoE++ and PoE+ devices to the same switch, which makes it ideal for powering and connecting multiple smart IoT appliances, such as intelligent LED lighting, smart building sensors and access points, IP cameras and surveillance systems. Lantronix will showcase these switches at ISC West, Booth 7117, in Las Vegas from April 10-12, 2024. The SM8TBT2SA, and SM24TBT4SA will be shipping in mass production in June 2024; and the SM24TBT4XPA, in July 2024. These PoE++ switches come pre-configured with Lantronix's Percepxion cloud management platform for secure control and visibility of Lantronix network switches. Percepxion benefits include the ability to perform firmware and configuration updates, automated monitoring, audit security logging administration and custom dashboards for network and PoE telemetry, all through a single pane of glass.

07:05 EDT Amylyx will reduce workforce by 70% - Amylyx announced a restructuring to focus the Company's financial resources on upcoming clinical milestones. The Company will reduce its workforce by approximately 70% and decrease external financial commitments outside of its priority areas. With these changes, Amylyx expects to have cash runway into 2026, which will allow the organization to deliver on key upcoming milestones, including data readouts from HELIOS, ORION, and its planned trial of AMX0114 in ALS.

07:04 EDT AerCap reports 152 assets leased, purchased and sold in Q1 - AerCap reported major Q1 business transactions: signed 82 lease agreements, including 6 widebody aircraft, 40 narrowbody aircraft, 26 engines and 10 helicopters; completed 21 purchases for 13 aircraft, 6 engines and 2 helicopters; completed 49 sale transactions for 35 aircraft, for 13 engines and 1 helicopter; repurchased approximately 4.3 million shares, at an average price of $77.89 per share, for a total of approximately $336M; signed financing transactions for approximately $1.6B.

07:02 EDT EnCore Energy reports results of Q1 at-the-market program - enCore Energy issued a total of 495,765 common shares between January 1 to March 31, 2024, under the at-the-market controlled equity offering program - ATM Program -. The shares were issued through TSXV and NASDAQ at an average share price of $4.05 per share for gross proceeds of $2,008,256.36 with a commission of $50,206.42 paid to the Agent. The last settlement date was January 16. The company has suspended its ATM Program with a remaining balance of approximately $18.7M of common shares available for sale. The company does not anticipate further sales under the ATM program in light of its current cash on hand of approximately $80M, zero debt, revenue from ongoing operations at the Rosita In-Situ Recovery Uranium Central Processing Plant and expected near term production revenue from the Alta Mesa CPP.

07:01 EDT Odyssey Therapeutics enters into a collaboration with Jannsen Pharmaceutica - Odyssey Therapeutics announced today it has entered into a strategic research collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to jointly discover and optimize small molecule medicines against select therapeutic targets. The companies will combine their expertise in artificial intelligence, machine learning, computational chemistry and drug discovery to unlock difficult-to-drug targets. The agreement was facilitated by Johnson & Johnson Innovation.

06:55 EDT Aecom consortium selected to deliver Australia's M80 Ring Road Completion - Aecom announced that the Victoria State Government has appointed Aecom, in partnership with Acciona and MACA Civil, as alliance non-owner participants to design and construct Australia's M80 Ring Road Completion between Plenty Road and the North East Link in Watsonia, Melbourne. Aecom will serve as the lead consultant and the only designer of the alliance and will play a central role in delivering the professional and technical services for the planning and design of permanent works.

06:49 EDT GFL Environmental board raises quarterly dividend 10% to 1.4c per share - GFL Environmental announced that the Board of Directors of the Company has declared a 10% increase to the regular quarterly cash dividend on the Company's subordinate voting and multiple voting shares. The regular quarterly cash dividend, which increases from 1.3c per share to 1.4c per share, will be paid on April 30, 2024 to shareholders of record at the close of business on April 15, 2024. The Company has designated this dividend as an eligible dividend within the meaning of the Income Tax Act.

06:48 EDT Lindsay CEO provides outlook - Lindsay CEO Randy Wood stated, "The USDA recently released the initial projection for 2024 U.S. net farm income which reflects a substantial decline compared to 2023 levels and was below broader market expectations. The forecasted decline, if realized, could negatively affect demand for irrigation equipment during the remainder of our fiscal 2024. We remain confident in the growth opportunity in South America end markets and Brazil in particular; however we expect current market conditions to temper demand for irrigation equipment at least in the near term. In our infrastructure business, we expect continued growth in our Road Zipper System lease revenues through increased construction activity supported by growth in U.S. infrastructure spending. We also continue to execute our Road Zipper System project sales pipeline, however the timing of implementation remains challenging to forecast due to the number of variables involved in executing these projects."

06:35 EDT Viavi shares milestones in 6G, AI research based on 6G Forward Program - Viavi Solutions shared milestones in 6G and AI research based on the company's 6G Forward Program. As 6G is the first AI-native generation of wireless communications, data sources such as a 6G city-scale digital twin will be vital for training other elements of the network such as the 6G AI-Native Air Interface. In 2022, VIAVI announced support for research at the Institute for Wireless Internet of Things and the Open6G cooperative research center at Northeastern University, as part of the VIAVI 6G Forward Program. A key aspect of the research was large-scale RF propagation channel modeling based on AI and ML technologies to develop a city-scale digital twin of a 6G network. The digital twin research has expanded to include: Use of AI/ML to augment ray tracing for radio frequency propagation modeling to drive the digital twin Conducting real-world measurement campaigns in the Northeastern Boston campus using the VIAVI Ranger rugged RF capture and playback instrument Incorporating higher-layer KPIs in the digital twin, to more effectively model effects of network conditions on application performance. The AI-Native Air Interface has appeared as a shift in the conventional methods of developing, standardizing, and commercializing communication technologies with the goal of effectively supplying data to applications while addressing communication problems and hardware limitations. In the physical layer of wireless communications, the neural receiver concept suggests replacing traditional signal processing blocks with trained AI models. To enable comprehensive testing of neural receivers, VIAVI has developed and demonstrated its own receiver as part of an end-to-end test and training environment.

06:32 EDT Haemonetics receives FDA clearance for TEG 6s Global Hemostasis-HN cartridge - Haemonetics has received 510(k) clearance from the U.S. Food and Drug Administration for the TEG 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adult cardiovascular surgeries/procedures and liver transplantation in both laboratory and point-of-care settings. The 510(k) clearance was supported by clinical data from a multi-center trial that included 335 patients undergoing cardiac bypass surgeries, interventional cardiology procedures or liver transplantations. An additional study was conducted using 164 healthy volunteers to establish the normal reference ranges for the test cartridge. Overall, over 5,500 clinical data points were used to demonstrate safety and effectiveness of the Global Hemostasis - HN assays.

06:16 EDT Epson announces revamped pricing, trade-in program - Epson announced it is making it easier for small businesses to upgrade their printers to more powerful models that enhance productivity. Small businesses can take advantage of Epson's revamped pricing across EcoTank Pro cartridge-free Supertank printers available through major retailers and on the Epson store. Additionally, users looking for a new printing solution can recycle an old printer in-store at select participating retailers for a discount on a new EcoTank model through the Trade In Trade Up program. Users can recycle their old printer from any manufacturer at select retailers including Best Buy, Office Depot, OfficeMax and Staples, and save up to $100 on an Epson EcoTank Pro and other select EcoTank models. This offer is currently eligible for in-store purchases only and not valid for orders placed online for in-store pickup.

06:03 EDT Wishpond Technologies launches SalesCloser AI - Wishpond Technologies announced the launch of SalesCloser AI, the Company's next generation AI-powered virtual sales agent. SalesCloser heralds a new era of personalized, round-the-clock sales calls and product demos for businesses without the need for human intervention. The platform can work 24/7 to engage leads, close deals, and deliver insights in ten different languages. SalesCloser can also be adapted for use across a diverse range of industries such as software/SaaS, professional services, financial services, education, travel & hospitality, insurance, and more.

06:01 EDT High Tide opens fifth Canna Cabana store in Ontario - High Tide announced that its Canna Cabana retail cannabis store located at 2901 Eglinton Avenue West, Mississauga, Ontario will begin selling recreational cannabis products and consumption accessories for adult use on Monday, April 8th. This opening will mark High Tide's 168th Canna Cabana branded retail cannabis location in Canada, the 59th in the province of Ontario and the 5th in the city of Mississauga.

05:57 EDT Grifols' Procleix ArboPlex Assay receives CE Mark - Grifols announced that its new Procleix ArboPlex Assay has obtained the CE mark under the In Vitro Diagnostic Regulation, the first for an automated nucleic acid test specifically validated for screening blood donors to detect four major arboviruses: chikungunya, dengue, West Nile and Zika viruses. The Procleix ArboPlex Assay will be available in all markets accepting the CE mark certification after completion of any additional registration and notification requirements.

05:54 EDT Assurant acquires iSmash, terms not disclosed - Assurant announced the acquisition of iSmash, the UK's leading independent tech repair brand, offering express drop-in repair services for smartphones, tablets and laptops. Founded in 2013, iSmash has grown to 38 convenient retail locations with 152 employees across the UK. iSmash will continue to operate as iSmash under the Assurant Global Connected Living line of business.